Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of BI 685509 with Food, Itraconazole, and Rifampin in Healthy Males
NCT03116893Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of avenciguat in chronic kidney disease (CKD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point at 4 days and Maximum measured concentration of the analyte in plasma at 4 days. Started Apr 2017; status: completed.
02
Drugs
avenciguat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03116893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03116893.